Epidemiology Laboratory
IRYCIS-Ramón y Cajal Hospital
HIV MOLECULAR EPIDEMIOLOGY LABORATORY
Our Lab
Our laboratory (EpiMolVIH) is integrated into the Microbiology Service of the Ramón y Cajal Hospital in Madrid, Spain, and belongs to the hospital’s Institute of Health Research (IRYCIS). For over 15 years, we have been researching HIV through national and international projects, where health cooperation and pediatric HIV are at the core of our work.
In our research lines, we explore viruses linked to various epidemics, such as HIV, SARS-CoV-2, and HCV, to thoroughly understand current epidemiological threats. Our mission extends beyond conventional epidemiological studies; we strive to lead the adoption of more effective molecular techniques, promote the use of suitable alternative samples in resource-limited settings, and develop new diagnostic methods based on nanotechnology through a variety of research projects.
EPIMOLBIO: Genetic Variability Analysis
Our Software
Genetic sequence analysis plays a crucial role in the field of modern medicine. However, many bioinformatics tools are costly or intricate, narrowing their user base and limiting global research collaboration. Our aim was to develop a user-friendly, versatile program for sequence analysis that can adapt to the user’s objectives.
EpiMolBio was initially developed in 2018 for HIV variability and drug-resistance studies. At the beginning of the COVID-19 pandemic, new functions were developed for mutation tracing and variant analysis, together with supplementary software for massive alignments, fasta file editing, and sequence processing. The software accommodates sequences in the widely-used .fasta format, alongside user-defined reference sequences to enable the study of various pathogenic organisms or other medically and biologically significant genomic entities.
EPIMOLBIO: Genetic Variability Analysis
Our Software
Genetic sequence analysis plays a crucial role in the field of modern medicine. However, many bioinformatics tools are costly or intricate, narrowing their user base and limiting global research collaboration. Our aim was to develop a user-friendly, versatile program for sequence analysis that can adapt to the user’s objectives.
EpiMolBio was initially developed in 2018 for HIV variability and drug-resistance studies. At the beginning of the COVID-19 pandemic, new functions were developed for mutation tracing and variant analysis, together with supplementary software for massive alignments, fasta file editing, and sequence processing. The software accommodates sequences in the widely-used .fasta format, alongside user-defined reference sequences to enable the study of various pathogenic organisms or other medically and biologically significant genomic entities.
